Effective Treatment Strategies for the Management of Diabetic Macular Edema
The live program has concluded.
If you attended, please click on the "Take Post-Test" button to claim your credit. If you did not attend, please stay tuned for the archived version, which will be available soon for on-demand viewing.
Overview
CONTENT SOURCE This continuing medical education (CME) activity captures content from a roundtable discussion held on May 1, 2016, in Seattle, WA. TARGET AUDIENCE This certified CME activity is designed for retina specialists and general ophthalmologists involved in the management of patients with retinal disease.A CME activity provided by Evolve Medical Education LLC and distributed with New Retina MD and Retina Today. Supported through an unrestricted educational grant by Alimera Sciences. Learning Objectives
Upon completion of this activity, the participant should be able to:
- Discuss the advantages and disadvantages of anti-VEGF therapy for patients with DME
- Recognize the clinical benefits of intravitreal steroid implant therapy, especially in patients that are refractory or have persistent DME
- Discuss the treatment of DR in the setting of DME with steroids
- Outline a patient-centric treatment protocol for the treatment of DME
Accreditation
ACCREDITATION STATEMENT
Evolve Medical Education LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Evolve Medical Education LLC designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Faculty and Disclosures
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.Nancy Holekamp, MD, moderator Pepose Vision Institute St. Louis, Missouri
Alexander M. Eaton, MD Retina Health Center Fort Myers, Florida
Matthew Ohr, MD Havener Eye Institute Columbus, Ohio
Charles C. Wycoff, MD, PhD Retina Consultants of Houston, Blanton Eye Institute Houston, Texas
It is the policy of Evolve Medical Education LLC that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve Medical Education LLC has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Nancy Holekamp, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of: Consultant/Advisory Board: Alimera Sciences; Allergan; Katalyst; Ophthotech Corporation; and Regeneron Pharmaceuticals. Grant/Research Support: Alimera Sciences; Allergan; Neurotech Pharmaceuticals; and Ophthotech Corporation. Stock Shareholder: Katylst.
Alexander M. Eaton, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of: Speaker’s Bureau: Alimera Sciences. Grant/Research Support: Acucela; Alcon; Alimera Sciences; Allergan; Apellis Pharmeceuticals; Genentech; Iconic Therapeutics; and Tyrogenex. Stock Shareholder: Alimera Sciences; Ophthotech Corporation; pSivida Corp; and Regeneron Pharmaceuticals.
Matthew Ohr, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of: Consultant/Advisory Board/Speaker’s Bureau: Alcon; Alimera Sciences; Allergan; Bayer Pharmaceuticals; Clearside Biomedical; DORC International; Genentech; ONL Therapeutics; Regeneron Pharmaceuticals; and ThromboGenics NV. Grant/Research Support: Merck & Co.; Ophthotech Corporation; Regeneron Pharmaceuticals; and Roche Pharma.
Charles C. Wykoff, MD, PhD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of: Consultant/Advisory Board/ Speaker’s Bureau: Alcon; Alimera Sciences; Allergan; Bayer Pharmaceuticals; Clearside Biomedical; DORC International; Genentech; ONL Therapeutics; Regeneron Pharmaceuticals; and ThromboGenics NV. Grant/Research Support: Acucela; Alcon; Allegro Ophthalmics LLC; Allergan; Ampio Pharmaceuticals; Apellis Pharmaceuticals; Clearside Biomedical; Genentech; Iconic Therapeutics; Ophthotech Corporation; pSivida Corp.; Regeneron Pharmaceuticals; Roche Pharma; Santen Pharmaceutical Co., Ltd.; ThromboGenics NV; and XOMA Ltd.
Cheryl Cavanaugh, MS, director of operations, Evolve Medical Education LLC; Michelle Dalton, medical writer; and Melanie Lawler, PhD, reviewer, have no financial relationships with commercial interests.
Disclaimer
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve Medical Education LLC, New Retina MD, Retina Today, or Alimera Sciences.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
Yewlin E. Chee, MD
Camila Ventura MD, PhD
Edward Wood, MD
Tony Capone Jr, MD
Katherine E. Talcott, MD
Nassim Abreu, MD
- CME/CE In-Person & Virtual Event
Treating Outside the Box: New Pathways to Retinal Vascular Stability
July 17, 2026
Montreal Katherine E. Talcott, MD
Roger A. Goldberg, MD, MBA
